Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | FABP7 | O15540 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11641269 | 0.81 | KDM4E (0.62) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL29514721 | 0.79 | KDM4E (0.69) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL357522 | 0.79 | KDM4E (0.69) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL9547527 | 0.75 | KDM4E (0.59) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL13984133 | 0.75 | EPHX1 (0.58) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL11291466 | 0.75 | NPC1 (0.79) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL30393282 | 0.75 | KDM4E (0.82) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL1276481 | 0.75 | KDM4E (0.82) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL6468790 | 0.74 | KDM4E (0.53) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL10599955 | 0.74 | ANPEP (0.53) | KDM4EGAARAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180296505-A1 | BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS | STC UNM (US) | 2018-10-18 | — | — | US | claimed |
| WO-2015126930-A2 | BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS | STC.UNM (US) | 2015-08-27 | — | — | WO | claimed |
| US-4183951-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-01-15 | — | — | US | claimed |
| US-20180296505-A1 | BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS | STC UNM (US) | 2018-10-18 | — | — | US | disclosed |
| US-20170056345-A1 | BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS | STC.UNM | 2017-03-02 | — | — | US | disclosed |
| WO-2015126930-A2 | BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS | STC.UNM (US) | 2015-08-27 | — | — | WO | disclosed |
| US-4225617-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-09-30 | — | — | US | disclosed |
| US-4209524-A | CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4209523-A | TREATMENT OF THE CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4183951-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-01-15 | — | — | US | disclosed |
| US-4152458-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1979-05-01 | — | — | US | disclosed |
| US-4151300-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC | LABORATOIRE L. LAFON (FR) | 1979-04-24 | — | — | US | disclosed |
| US-4122186-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296505-A1 | BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS | TREH, ACHE, UMPS | KDM4E 1077/4885GAA 9/4885RAB9A 3650/4885 |
| US-20170056345-A1 | BOOSTER DRUG THERAPY FOR MYCOBACTERIUM INFECTIONS | TREH, ACHE, UMPS | KDM4E 1077/4885GAA 9/4885RAB9A 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.